Cytokines have an important role in the initiation and amplification of the inflammatory response in the mucosa, 1 and genes involved in the regulation of their activity clearly constitute important candidate susceptibility loci for inflammatory bowel disease (IBD). However, several studies focusing on genes encoding immunoregulatory cytokines such as tumour necrosis factor ␣ and interleukin 1 receptor antagonist (IL-1RA) have produced conflicting results. 2, 3 Although the reasons for this disagreement remain unclear, ethnic differences and disease heterogeneity with variable case mix with regards to the extent of the disease might explain some of the apparently conflicting results among different studies. Interleukin-4 (IL-4) has been considered an important cytokine in mucosal immunity. T cell receptor ␣ deficient mice spontaneously develop colitis associated with an increase in the number of IL-4 producing cells, and, the development of colitis can be prevented by pre-treatment with an anti-IL-4 monoclonal antibody. 4, 5 Double mutant mice created by crossing T cell receptor ␣ deficient mice with IL-4 deficient mice do not develop colitis emphasising the critical role of IL-4 in the pathogenesis of colitis in this model. 6 In humans, the administration of IL-4 in cancer therapy is often associated with a diarrhoeal ill- ness associated with mucosal ulceration 7 and the early ileal lesions in patients with Crohn's disease (CD) after ileal resection are associated with a significant increase in IL-4 mRNA in mucosal biopsies. 8 The gene for IL-4 has been mapped to the long arm (q23-31) of chromosome 5. 9 A C→T exchange has been identified at position −590 in the promoter region of IL-4 and the variant allele has been suggested to be associated with increased transcriptional activity as well as enhanced IgE secretion. 10, 11 Associations between this promoter region polymorphism and susceptibility to bronchial asthma, atopic dermatitis and rheumatoid arthritis have been reported, but these associations have not been confirmed in all studies, with for example the IL-4 variant being reported to be a risk factor for asthma in US and Japanese patients, but not in UK and Australian families. [12] [13] [14] [15] Recently, a C→T substitution has been identified at position −34 in the untranslated region that is in linkage disequilibrium with the polymorphism at position −590 in the promoter region. 16 The same polymorphism has also been identified in another study but was referred to as +33 due to numbering from the start of exon 1 of the mature message rather than from the start of the open reading frame as has been done for the −590 polymorphism. 17 The IL-4 receptor (IL-4R) comprises of two subunits: a 140-kd ␣ subunit, which binds IL-4 and transduces its growth promoting and transcription-activating functions and a ␥ subunit, common to several cytokine receptors, which amplifies signalling by the ␣ subunit. 18, 19 The IL-4R␣ gene is located on the short arm of chromosome 16 in the 16p12 band. A novel IL-4R ␣ allele has been identified in which G→A substitution at position 1902 results in a change from glutamine to arginine at aminoacid 576 (or 551 if the signal peptide is not included in the numbering) of the interleukin-4 receptor ␣. The variant IL-4R␣ R 576 allele appears to be associated with enhanced signalling activity and has been suggested to be more common in patients with atopy though this has not been confirmed in all studies. [20] [21] [22] Previous genome wide scans in IBD families have identified putative CD susceptibility loci in the pericentromeric region of chromosome 16, which contains the IL-4 receptor gene, 23 and in a chromosomal segment corresponding to 5q31-33 containing the IL-4 gene. 24 In a recent UK-based family study, no evidence for association between IL-4R haplotype for several SNPs including that for the Q576R substitution and susceptibility to either CD or ulcerative colitis (UC) was detected. 25 However, there appear to have been no previous studies on the relationship between susceptibility to either CD and UC and genotype for IL-4 and we have therefore performed an allelic association study to examine the role of polymorphisms in the IL-4 gene in determining the susceptibility to UC and CD. Since overall IL-4 signalling activity is likely to be dependent on both IL-4 and on signalling by its receptor, we also determined the role of the Q576R polymorphism for IL-4R in susceptibility, since, though this polymorphism alone appears not to be a risk factor, 25 combined genotypes for both genes might affect risk of disease.
Ninety-eight patients with UC (50 left sided, 48 extensive), 86 with CD (21 small bowel, 28 large bowel, 37 both) were recruited from the gastroenterology clinic at the Freeman Hospital, Newcastle upon Tyne, UK. Diagnosis in all patients was confirmed on clinical, colonoscopic, (or radiological in cases of small bowel Crohn's disease) as well as histological grounds to be either ulcerative colitis (UC) or Crohn's disease (CD). Demographic details are shown in Table 1 . All the patients and 321 healthy local controls were Caucasians and were unrelated.
After obtaining informed consent blood (10 ml) was collected from all the subjects and genomic DNA prepared as described by Daly et al, 1996 . 26 Genotyping for the polymorphism at position −34 in the IL-4 gene and codon 576 in the IL-4R␣ gene were performed by PCR- a Disease extent in ulcerative colitis was defined as the most proximal extent of the disease at the most recent colonoscopy or at colectomy. If macroscopic extent differed from the microscopic assessment, the microscopic extent was used for disease classification. Thus, disease was classified as distal colitis if inflammation was restricted to the colon distal to splenic flexure or as extensive colitis if inflammation extended proximally. Disease extent in Crohn's disease was defined from the most recent radiological, endoscopic and histologic data. Patients were grouped as both small bowel and large bowel involvement (including ileo-caecal disease), exclusively large bowel disease (including perianal disease) and exclusively small bowel disease.
RFLP analysis as shown in Figures 1 and 2 . Both assays were validated by sequencing individuals of representative genotypes. The frequency distribution of genotypes for both the −34 IL-4 polymorphism and the codon 576 IL-4R␣ polymorphism in the patient groups and controls are shown in Tables 2 and 3. Significantly higher proportion of patients with CD Figure 1 Genotyping for the IL-4 -34 polymorphism: Primers IL4P2 (5Ј-GATTTGCAGTGACAATGTGAG-3Ј) and IL4P3 (5Ј-TCCTATGCTGAAACTTTGTAG-3Ј) were used for PCR amplification using the general conditions described previously. 26 The PCR conditions consisted of 30 cycles of 94°C for 1 min denaturation, 57°C for 1 min annealing and 72°C for 1 min extension followed by 1 cycle at 70°C for 10 min. The PCR product was diluted to 1/50 and 1 l was used for a second nested PCR using primers IL4P1 (5Ј-AAGTGACTGACAATCTGGTGA-3Ј) and IL4P2 (5Ј-GATTTGCAGTGACAATGTGAG-3Ј) with the same conditions as the first PCR. IL4P1 has a mismatch present (indicated in bold) which introduces a BsmAI site into samples positive for the variant sequence. The 156 bp PCR product was digested with BsmA1 at 55°C and analysed by electrophoresis on a 10% acrylamide gel. BsmA1 cleaves only products containing T at position −34 into 143 and 13 bp fragments. The gel photograph shows a homozygous mutant sample in lanes 1, heterozygotes in lanes 2 and 4 and homozygous wild-type samples in lanes 3 and 5.
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Figure 2
Genotyping for the IL-4R␣ polymorphism: Primers IL4R1 (5Ј-TCGGCCCCACCAGTGGCGATC-3Ј) and IL4R2 (5Ј-CCAGTCCAAGGTGAACAAGGGG-3Ј) were used for PCR amplification using the general methods described previously. 26 The PCR conditions consisted of 30 cycles of 94°C for 1 min denaturation, 67°C for 1 min annealing and 72°C for 1 min extension followed by 1 cycle at 70°C for 10 min. Primer IL4R1 had a mismatch (indicated in bold) present which introduced a PvuI site into samples positive for the variant sequence. The 266 bp PCR product was digested with PvuI at 37°C in PCR buffer and analysed by electrophoresis on a 10% acrylamide gel. PvuI cleaves the mutant allele into 248 and 18 bp fragments. The gel photograph shows wild-type homozygous samples in lanes 1 and 4, a homozygous mutant in lane 2 and a heterozygote in lane 3. (32%) carried one or more variant T alleles (TT/TC genotype) when compared with controls (16%) (P = 0.002; OR 2.4 (1.41-4.18)). The IL-4-34 polymorphism was in complete linkage disequilibrium with the functionally significant C-590T polymorphism (unpublished data) in this Caucasian group as described previously for Japanese subjects. 16, 17 A trend towards an association of the variant R 576 IL-4R␣ allele was detected with 41% of patients with CD carrying one or more R 576 alleles compared to 31% of the control group (P = 0.09; OR 1.6(0.94-2.7)). Combined genotypes for both polymorphisms were also investigated since positivity for the IL-4 −34 T allele and the IL-4 R576 allele would be predicted to result in both increased production of IL-4 and increased receptor signalling. The results are presented in Table 4 . Significantly higher proportion of patients with CD (15%) carried combination of both (IL-4 and IL-4 receptor) variant alleles compared with 4% of the controls (P = 0.005; OR 4.5(1.55-13.20)).
Existing both in vitro and in vivo data suggest that the −590 T allele (linked to −34T) is associated with increased IL-4 expression. [10] [11] [12] [13] [14] Similarly, the variant IL-4R␣ R 576 allele also has been reported to be associated with enhanced receptor activity. 20, 21 The association of variant alleles resulting in increased production and activity of IL-4 with CD suggests a role for IL-4 in disease susceptibility. Even though, similar to a recent study, 25 no statistically significant association was detected in our group between Q576R substitution in the IL-4 receptor gene and CD, we found a strong association between a combination of both (IL-4 and IL-4 receptor) variant alleles and CD. Association with alleles resulting in high IL-4 transcription and enhanced signalling activity suggests that IL-4 may have a role in the pathogenesis of Crohn's disease. IL-4 is an important cytokine in the development of a mucosal immune response to luminal antigens. 27 Several studies have suggested a role for luminal bacteria in the pathogenesis of CD. [28] [29] [30] In diseases caused by intracellular pathogens, the type 1 cytokines exert a protective effect by bacterial elimination, while type 2 cytokines such as IL-4 inhibit such a response. 31 As IL-4 also attenuates the barrier function of the intestinal epithelium, 32 increased IL-4 actually may promote enhanced translocation of luminal pathogens across the mucosa and further prevent effective bacterial elimination.
Although it is generally believed that UC and CD have different patterns of cytokine production with a relative excess of T-helper (Th) 1 cytokines in CD and Th2 cytokines in UC, the Th1/Th2 paradigm may be an over-simplification of the mucosal immune response in IBD. 1, 33 The studies measuring mucosal mRNA levels for cytokines are difficult to interpret as there is little information on the specific disease phenotype, stage of the disease or anatomical location of biopsy specimens, and all these factors may influence cytokine mRNA expression. 8, 33 The early ileal lesions in patients with CD after ileal resection are associated with a significant increase of IL-4 mRNA in the mucosal biopsy suggesting a role for IL-4 in the recurrence of the disease. 8 Interestingly, 15 out of 17 patients in this study had ileal resection for symptomatic stenosis though these findings need to be confirmed in a larger group. 8 IL-4 has been shown to promote collagen synthesis and fibrosis in different tissues such as liver, skin and lung [34] [35] [36] and IL-4 may therefore be responsible for the fibrotic stricture formation that characterises CD. A larger study with wellcharacterised sub-groups with specific disease phenotypes will be able to test this hypothesis.
